HUNTER HEART-RA-2 (HHRA-2) STUDYA Randomised Controlled Trial Evaluating the Effects of Humira Upon Endothelial Function in ACPA-Positive and ACPA-Negative Patients with Rheumatoid Arthritis.

At a glance
Trial Overview
Trial Details
Interventions
Trial Centres
- Investigators
- Centres
Trial History
References

Trial Profile

HUNTER HEART-RA-2 (HHRA-2) STUDYA Randomised Controlled Trial Evaluating the Effects of Humira Upon Endothelial Function in ACPA-Positive and ACPA-Negative Patients with Rheumatoid Arthritis.

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 23 Nov 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Adalimumab (Primary)
Indications Rheumatoid arthritis
Focus Therapeutic Use
Acronyms HUNTER HEART-RA-2 (HHRA-2) STUDY

Most Recent Events

17 Nov 2020 Planned End Date changed from 1 Jun 2016 to 24 Nov 2017.
17 Nov 2020 Status changed from not yet recruiting to discontinued.
05 Jun 2015 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com